Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

HUTCHMED’s savolitinib clinches priority review for gastric cancer in China

HUTCHMED (NASDAQ:HCM) announced on Tuesday that Chinese regulators have accepted its New Drug Application (NDA) for savolitinib and granted it priority review, clearing a path for the drug to become the first selective MET inhibitor approved for gastric cancer in the region.

Leia mais: HUTCHMED’s savolitinib clinches priority review for gastric cancer in China